

Inhibin B Gen II ELISA

Instruction for use in local language is available at beckmancoulter.com/techdocs.

REVISION HISTORY

Previous version: IFU-A81303-05	Current version: IFU-A81303-06
—	Adding Kazakh and Slovak to the IFU.

REF A81303

FOR PROFESSIONAL USE ONLY

INTENDED PURPOSE

Inhibin B Gen II ELISA is an in vitro diagnostic manual medical device intended to be used by healthcare professionals for the quantitative measurement of Inhibin B in human serum and plasma. Measurement of Inhibin B is intended to be used as an aid in diagnosis and monitoring of granulosa cell cancer in women; in males for evaluation of fertility status and as aid in diagnosis of anorchia [1, 2, 3, 4, 5].

PRINCIPLE

The enzyme immunoassay of inhibin B is an enzymatically amplified three-step sandwich-type assay. Mouse monoclonal antibodies directed against two different epitopes of inhibin B and hence not competing are used.

Samples and calibrators are first incubated in wells coated with the monoclonal antibody. After the first incubation, the contents of the wells are rinsed and the wells are incubated with biotinylated detection antibody. After the second incubation, the contents of the wells are rinsed and the wells are incubated with streptavidin labeled with the enzyme horseradish peroxidase (HRP). After the third incubation the contents of the wells are rinsed and the wells are incubated with the substrate tetramethylbenzidine (TMB). The bound enzymatic activity is then measured after the addition of a chromogenic substrate. The inhibin B concentrations in the samples are obtained by interpolation from the standard curve. The concentration of inhibin B in the samples is directly proportional to the absorbance.

WARNING AND PRECAUTIONS

General remarks:

- Avoid exposure of the reagents to excessive heat or direct sunlight during storage and incubation.
- Do not mix the reagents from kits of different lots.
- A standard curve must be established with each assay.
- It is recommended to perform the assay in duplicate.
- Each well must be used only once.
- Incomplete washing will adversely affect the outcome and assay precision.
- Avoid microbial contamination of reagents, especially of the conjugate and the assay buffer.
- Avoid contamination of the TMB chromogen solution with the conjugates.
- For dispensing sulfuric acid and TMB chromogen solution, avoid pipettes with metal parts.
- The enzyme used as the label is inactivated by oxygen, and is highly sensitive to microbial contamination, sodium azide, hypochlorous acid and aromatic chlorohydrocarbons often found in laboratory water supplies.

Materials of human origin

All patient specimens should be handled as potentially infectious and waste should be discarded according to the country rules.

The summary of safety and performance for this in vitro diagnostic medical device is available to the public in the European database on medical device (EUDAMED) when this database is available, and the information has been uploaded by the Notified Body. The web address of the EUDAMED public web site is: <https://ec.europa.eu/tools/eudamed>.

To search the information about this product in EUDAMED, use BUDI-DI: 150995905A81303SU

GHS HAZARD CLASSIFICATION

Assay Buffer

WARNING



H316
H317

Causes mild skin irritation.
May cause an allergic skin reaction.

	H319	Causes serious eye irritation.
	H412	Harmful to aquatic life with long lasting effects.
	P273	Avoid release to the environment.
	P280	Wear protective gloves, protective clothing and eye/face protection.
	P332+P313	If skin irritation occurs: Get medical advice/attention.
	P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
	P337+P313	If eye irritation persists: Get medical advice/attention.
	P362+P364	Take off contaminated clothing and wash it before use. Alcohol, C12-14-secondary, ethoxylated 1 - < 3% reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%
Biotin Conjugate Diluent	WARNING	
		
	H316	Causes mild skin irritation.
	H317	May cause an allergic skin reaction.
	H319	Causes serious eye irritation.
	H412	Harmful to aquatic life with long lasting effects.
	P273	Avoid release to the environment.
	P280	Wear protective gloves, protective clothing and eye/face protection.
	P332+P313	If skin irritation occurs: Get medical advice/attention.
	P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
	P337+P313	If eye irritation persists: Get medical advice/attention.
	P362+P364	Take off contaminated clothing and wash it before use. Alcohol, C12-14-secondary, ethoxylated 1 - < 3% reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%
AB Biotin Conjugate Concentrate	DANGER	
		
		
	H316	Causes mild skin irritation.
	H317	May cause an allergic skin reaction.
	H318	Causes serious eye damage.
	H412	Harmful to aquatic life with long lasting effects.
	P273	Avoid release to the environment.
	P280	Wear protective gloves, protective clothing and eye/face protection.
	P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

	P310	Immediately call a POISON CENTER or doctor/physician.
	P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
	P362+P364	Take off contaminated clothing and wash it before use. Alcohol, C12-14-secondary, ethoxylated 3 - 6% reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%
Streptavidin Conjugate RTU	DANGER	
		
		
		
	H226	Flammable liquid and vapour.
	H302	Harmful if swallowed.
	H313	May be harmful in contact with skin
	H370	Causes damage to organs.
	P210	Keep away from heat, hot surfaces, and sparks. No smoking.
	P280	Wear protective gloves, protective clothing and eye/face protection.
	P308+P311	If exposed or concerned: Call a doctor/physician.
	P312	Call a POISON CENTER or doctor/physician if you feel unwell. Methanol 1 - 9%
Stopping Solution A	DANGER	
		
	H314	Causes severe skin burns and eye damage.
	P280	Wear protective gloves, protective clothing and eye/face protection.
	P301+P330+P331	IF SWALLOWED: rinse mouth. Do NOT induce vomiting.
	P303+P361+P353	IF ON SKIN (or hair): Rinse skin with water.
	P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
	P310	Immediately call a POISON CENTER or doctor/physician. Sulfuric Acid 1 - 3%
Wash Solution U (20X)	DANGER	
		
	H360	May damage fertility or the unborn child.
	P201	Obtain special instructions before use.
	P280	Wear protective gloves, protective clothing and eye/face protection.
	P308+P313	IF exposed or concerned: Get medical advice/attention. Boric Acid 0.1 - < 0.3% Sodium Borate Decahydrate 0.1 - < 0.3%

SPECIMEN COLLECTION, PROCESSING, STORAGE AND DILUTION

- Serum and lithium heparin plasma are the recommended sample types.
- Allow serum samples to clot completely before centrifugation.
- Within two hours after centrifugation, transfer at least 500 µL of cell-free sample to a storage tube. Tightly stopper the tube immediately.
- Serum and plasma samples may be stored at 2-8°C, if the assay is to be performed within 48 hours. For longer storage keep frozen (< -18°C, one year maximum), after aliquoting so as to avoid repeated freezing and thawing. Thawing of sample should be performed at room temperature.
- If samples have concentrations greater than the highest calibrator, they must be diluted into the zero calibrator.

Use the following guidelines when preparing samples:

- Ensure residual fibrin and cellular matter have been removed prior to analysis.
- Follow blood collection tube manufacturer's recommendations for centrifugation.

Serum and lithium heparin plasma values for 120 samples (serum values ranging from 0.00 to 556.6 pg/mL) were compared using the Inhibin B Gen II ELISA. Results are as follows: [Li-Hep plasma] = 0.972[serum]+0.000; R = 0.995

MATERIALS PROVIDED

All reagents of the kit are stable until the expiry date indicated on the kit label, if stored at 2-8°C. Expiry dates printed on vial labels apply to the long-term storage of components by the manufacturer only, prior to assembly of the kit. Do not take them into account.

Storage conditions for reagents after dilution are indicated in paragraph Procedure.

Plate: 12 x 8 wells (ready-to-use)

Unused strips have to be stored at 2-8°C in the self-lock bag provided.

Antibody-Biotin conjugate concentrate: one 0.4 mL vial

The vial contains a solution of biotinylated anti-inhibin α -subunit antibody in buffer with protein (mouse), ProClin \ddagger 300 (<0.5%).

Streptavidin-Enzyme conjugate: one 13.0 mL bottle (ready-to-use)

The bottle contains conjugated HRP in buffer with protein (fish) and methanol (<10%).

Assay buffer: one 8 mL bottle (ready-to-use)

The bottle contains buffer with bovine serum albumin (BSA), protein (bovine, mouse, goat), surfactant, and ProClin \ddagger 300 (<0.5%).

Biotin conjugate diluent: one 13 mL bottle (ready-to-use)

The bottle contains buffer with BSA, protein (bovine, mouse, goat), surfactant and ProClin \ddagger 300 (<0.5%).

TMB Chromogen solution: one 11 mL bottle (ready-to-use)

The bottle contains a solution of TMB in citrate buffer with hydrogen peroxide.

TMB Chromogen solution (11 mL) may be ordered separately, too (REF. DSL-10-9755-1).

Wash solution U (20X): one 50 mL vial

Concentrated solution has to be diluted before use. It may be ordered separately, too (REF. A54825).

Stopping solution A: one 11 mL bottle (ready-to-use)

The bottle contains 0.2 M sulfuric acid.

Stopping solution A (11 mL) may be ordered separately, too (REF. C24811).

MATERIALS REQUIRED, BUT NOT PROVIDED

In addition to standard laboratory equipment, the following items are required:

- **Inhibin B Gen II Calibrators and Controls, supplied upon REF. A81304.**
- Orbital microtiter plate shaker.
- Precision pipette to deliver 10–1,000 µL.
- Microtiter plate washer (optional).
- Vortex type mixer.
- Absorbent material for blotting strips.
- Microtiter plate reader (450/405 nm and 600-630 nm) (bichromatic reading).

PROCEDURE

Preparation of reagents

Let all the reagents come to room temperature and mix them thoroughly by gentle inversion before the use.

Preparation of the wash solution

Pour the content of the vial into 950 mL of distilled water and homogenize. The diluted solution can be stored in a tightly sealed bottle at 18-25°C one month or at 2-8°C until the expiry date of the kit.

Preparation of the Antibody-Biotin conjugate concentrate

The Antibody-Biotin conjugate concentrate should be freshly diluted 10-30 minutes before use. For an entire plate, pipette exactly 220 µL of the Antibody-Biotin conjugate concentrate into 11 mL of the Biotin conjugate diluent. The Antibody-Biotin conjugate concentrate should be diluted at a ratio of 1 part into 50 parts of Biotin conjugate diluent, according to the number of wells used.

Microtitration wells

Select the number of coated wells required for the assay. The remaining unused wells should be placed in the resealable pouch with a desiccant. The pouch must be resealed to protect from moisture.

Assay procedure

Step 1 Additions, 1 st incubation	Step 2 2 nd incubation	Step 3 3 rd incubation
To coated wells add successively: 50 µL of calibrator, control or sample and 50 µL of Assay buffer. Incubate 2 hours at 18-25°C with shaking (600-800 rpm).	Aspirate carefully the contents of each well. Wash 5 times with 350 µL of the wash solution using an automatic microplate washer or manually using a precision pipette. Blot and dry by inverting plate on absorbent material. Add 100 µL of Antibody-Biotin conjugate solution to each well. Incubate 1 hour at 18-25°C with shaking (600-800 rpm).	Aspirate carefully the contents of each well. Wash 5 times with 350 µL of the wash solution using an automatic microplate washer or manually using a precision pipette. Blot and dry by inverting plate on absorbent material. Add 100 µL of Streptavidin-Enzyme conjugate solution to each well. Incubate 30 minutes at 18-25°C with shaking (600-800 rpm).
Step 4 Enzymatic step	Step 5 Reading	
Aspirate carefully the contents of each well. Wash 5 times with 350 µL of the wash solution using an automatic microplate washer or manually using a precision pipette. Blot and dry by inverting plate on absorbent material. Add 100 µL of chromogenic substrate to each well.* Incubate 8-12 minutes at 18-25°C with shaking (600-800 rpm).**	Add 100 µL of stop solution to each well.*** Read absorbance within 30 minutes at 450 nm.****	

*Avoid exposure to direct sunlight.

**Be aware that color may develop more quickly or more slowly than the recommended incubation time depending on the localized room temperature. Visually monitor the color development to optimize the incubation time.

***To minimize potential assay drift due to variation in the substrate incubation time, care should be taken to add the stopping solution into the wells in the same order and speed used to add the TMB chromogenic solution.

****If wavelength correction is available, set the instrument to dual wavelength measurement at 450 nm with background wavelength correction set between 600-630 nm.

RESULTS

Results are obtained from the calibrator curve by interpolation. The curve serves for the determination of analyte concentrations in samples measured at the same time as the calibrators.

Standard curve

The results in the quality control department were calculated using *weighted cubic regression* curve fit with ABS on the log vertical axis and analyte concentration of the calibrators on the log horizontal axis.

Other calculation methods may give slightly different results.

Calibrators	Inhibin B (pg/mL)	ABS	ABS/ABS _{max} (%)
0	0	0.042 (blank)	-
1	11	0.081	2.60
2	33	0.166	5.32
3	110	0.460	14.8
4	275	0.995	31.9
5	550	1.744	55.9
6	1,100	3.118	100

· ABS = Absorbance

(Example of standard curve, do not use for calculation. Use the concentration of calibrators indicated on each vial label. The concentrations are lot specific, check carefully.)

Samples

For each sample, locate ratio ABS on the vertical axis and read off the corresponding analyte concentration on the horizontal axis.

EXPECTED VALUES

We recommend each laboratory to establish its own reference values. The following values obtained from healthy subjects are indicative only.

Serum samples were procured either from vendors or were aliquots stored in freezers from our previous studies. These samples were analyzed using the Inhibin B Gen II kit on site. The expected ranges for inhibin B were calculated using 85-95% non-parametric estimation using Analyse-it^{†††} for Microsoft Excel^{†††}.

Samples	n	Median age (years)	Median	2.5 th - 97.5 th percentile
			(pg/mL)	
Random males	235	35	166	25-325
Random females	95	30	47	ND-341
Females 3 rd day of cycle	106	NA	75	ND-273
Post menopausal females [†]	20	74	ND	ND-5.79
Boys ^{††}	15	11	93	4-352
Girls	15	11	18	ND-83

· ND = Non-Detectable

†. 90% non-parametric

††. 85% non-parametric

QUALITY CONTROL

Good laboratory practices imply that control samples be used regularly to ensure the quality of the results obtained. These samples must be processed exactly in the same way as the assay samples, and it is recommended that their results be analyzed using appropriate statistical methods.

Failure to obtain the appropriate values for controls may indicate imprecise manipulations, improper sample handling or deterioration of reagents.

In case of packaging deterioration or if data obtained show some performance alteration, please contact your local distributor or use the following e-mail address: imunochem@beckman.com

According to EU regulation 2017/746, any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of EU Member State in which the user and/or patient is located.

PERFORMANCE CHARACTERISTICS

(For more details, see the data sheet "APPENDIX")

Representative data are provided for illustration only. Performance obtained in individual laboratories may vary.

Sensitivity

Limit of detection (LoD): 5.42 pg/mL

The LoD of the assay is 5.42 pg/mL, determined consistent with guidelines in CLSI document EP17-A2 [6] based on the proportions of false positives (α) less than 5% and false negatives (β) less than 5%; using determinations, with 168 blank and 168 low level samples; and Limit of Blank (LoB) of 1.83 pg/mL.

Specificity

The highly characterized antibody pair used in the assay measures 100% inhibin B in human, monkey and rat. The following potential cross reactants (inhibin A, activin A, activin B, activin AB, AMH, FSH, LH and Follistatin 315) were added at least at two times their physiological concentration to serum matrix and assayed. All inhibin B values obtained in the presence of each cross reactant were non-detectable.

Precision

Repeatability and within-laboratory precision

The precision of the assay was determined consistent with guidelines in CLSI document EP05-A3 [7]. For repeatability the coefficients of variation were found below or equal to 12.8 % for serum samples. For within-laboratory precision the coefficients of variation were found below or equal to 14.3 % for serum samples.

Accuracy

Linearity

The assay demonstrated to be linear from 5.88 to 1,264 pg/mL using serum samples (determined consistent with guidelines in CLSI document EP06-A [8]).

Dilution test

High-concentration samples were serially diluted with the zero calibrator. The recovery percentages obtained were between 92.9% and 110%.

Recovery test

Low-concentration samples were spiked with known quantities of Inhibin B. The recovery percentages obtained were between 94.5% and 105%.

Measurement range (from LoD to the highest calibrator): 5.42 to approximately 1,000 pg/mL.

LIMITATIONS

Failure to follow these instructions for use (IFU) may significantly affect results.

Results should be interpreted in the light of the total clinical presentation of the patient, including clinical history, data from additional tests and other appropriate information.

Do not use hemolyzed, lipemic or icteric samples. For more details, see Appendix, § Interference.

In immunoassays, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Immunoassays may be also affected by presence of anti-avidin or anti-streptavidin antibodies, as well as by the presence of autoantibodies directed against the determined analyte. Such interfering antibodies may cause erroneous results. Carefully evaluate the results of patients suspected of having these antibodies [9, 10, 11].

If there is evidence of microbial contamination or excessive turbidity in a reagent, discard the vial.

“Hook effect“: there is no hook effect, when the two-step procedure is used [12].

APPENDIX

PERFORMANCE CHARACTERISTICS

Representative data are provided for illustration only. Performance obtained in individual laboratories may vary.

Summary

Inhibins are heterodimeric polypeptide hormones. They selectively suppress the secretion of pituitary follicle stimulating hormone (FSH) and also have local paracrine actions on the gonads [13,14]. The fully processed form of the inhibin molecule has a molecular weight of approximately 32-36 kD and consists of the two distinct chains (α and β), linked by disulfide bridges. Higher molecular weight forms, with precursor forms of the α -subunit, also occur in follicular fluid and serum. In addition, free α -subunit forms, unassociated with a β -subunit, and lacking inhibin bioactivity, are also present [15,16,17,18].

Inhibin B consists of an α -subunit and a β -subunit. Inhibin B is produced by the sertoli cells of the testis in the male and the granulosa cells of the ovary in the female. Its primary role appears to be in the regulation of gametogenesis via negative feedback on the production of FSH. Several published reports indicate the utility of measurement of inhibin B as an endocrine marker for monitoring the male [19,20,21,22,23,24] and female [25,26,27,28,29,30,31,32,33] gonadal function.

The Inhibin B Gen II ELISA uses the highly characterized pair of antibodies that specifically recognize only the functional dimeric inhibin B molecule and does not measure the free α -subunit forms present in biological fluids [34]. The current assay does not require sample pre-treatment step with hydrogen peroxide to oxidize two methionines in the epitope to the sulfoxide for full immunoreactivity.

Interference

Serum samples containing inhibin B concentrations (low and high) were spiked with multiple concentrations of the substances listed below and assayed using Inhibin B Gen II ELISA. Values were calculated as described in CLSI EP07, 3rd ed. [35]. Interference was determined by testing controls (no interfering substance added) and matched test samples (with interfering substance added). No interference (defined as a shift in dose > 15 %) was found for addition of interferent up to concentration stated in the table below.

Interferent	Test concentration
Acetylsalicylic acid	48.1 $\mu\text{g/mL}$
Ascorbic acid	58.7 $\mu\text{g/mL}$
Biotin	1,694 ng/mL
Conjugated bilirubin	443 $\mu\text{g/mL}$
Hemoglobin	10,013 $\mu\text{g/mL}$
Heparin	8,003 ng/mL
Cholesterol	4.52 mg/mL
Ibuprofen	340 $\mu\text{g/mL}$
Prednisone	117 ng/mL
Prednisolone	1,343 ng/mL
Rheumatoid factor	37.0 IU/mL
Triglycerides	16.4 mg/mL
Unconjugated bilirubin	200 $\mu\text{g/mL}$

In spite of hemoglobin, bilirubin (conjugated, unconjugated) and triglyceride interference data in the table, we advise to avoid using hemolyzed, lipemic or icteric samples.

Precision

Repeatability and within-laboratory precision

Samples were assayed for 20 days, 2 runs per day, in triplicates per run. Assays were performed by two lab technicians, by two reagent lots. There were 120 individual measurements per sample with no invalid results.

Serum samples	Mean (pg/mL)	Repeatability		Within-laboratory precision	
		SD (pg/mL)	C.V. (%)	SD (pg/mL)	C.V. (%)
S1	20.1	2.57	12.8	2.84	14.2
S2	29.0	3.04	10.5	3.67	12.6
S3	111	5.21	4.68	11.7	10.6
S4	235	18.1	7.70	27.4	11.7
S5	546	48.8	8.95	62.7	11.5
S6	898	66.1	7.36	128	14.3

Li-Hep plasma samples	Mean (pg/mL)	Repeatability		Within-laboratory precision	
		SD (pg/mL)	C.V. (%)	SD (pg/mL)	C.V. (%)
P1	50.3	3.69	7.34	4.08	8.12
P2	93.6	5.53	5.91	6.47	6.91
P3	158	6.97	4.40	8.86	5.60
P4	425	44.7	10.5	44.7	10.5
P5	658	40.4	6.14	47.7	7.25
P6	989	43.5	4.40	62.0	6.27

Accuracy**Linearity**

The assay demonstrated to be linear from 5.42 (LoD) to 1,153 pg/mL using lithium heparin plasma samples (determined consistent with guidelines in CLSI document EP06-A [8]).

Dilution test

Samples were diluted in zero calibrator and assayed according to the assay procedure of the kit.

Serum samples	Dilution factor	Inhibin B (pg/mL)		Ratio (%) Measured/Expected
		Measured	Expected	
S1	-	1,032	-	-
	1:2	552.4	515.8	107.1
	1:4	284.2	257.9	110.2
	1:8	140.4	128.9	108.9
	1:16	66.17	64.47	102.6
S2	-	701.2	-	-
	1:2	344.4	350.6	98.24
	1:4	176.6	175.3	100.8
	1:8	88.79	87.66	101.3
	1:16	42.39	43.83	96.72
S3	-	606.7	-	-
	1:2	300.8	303.4	99.15
	1:4	145.9	151.7	96.20
	1:8	74.57	75.84	98.32
	1:16	35.24	37.92	92.93

Li-Hep plasma sample	Dilution factor	Inhibin B (pg/mL)		Ratio (%) Measured/Expected
		Measured	Expected	
P1	-	743.3	-	-
	1:2	359.1	371.7	96.63
	1:4	188.6	185.8	101.5
	1:8	93.85	92.91	101.0
	1:16	47.77	46.46	102.8
P2	-	676.0	-	-
	1:2	312.6	338.0	92.49
	1:4	159.9	169.0	94.62
	1:8	85.21	84.50	100.8
	1:16	42.82	42.25	101.4
P3	-	1158	-	-
	1:2	578.3	579.0	99.87
	1:4	283.6	289.5	97.97
	1:8	137.7	144.8	95.11
	1:16	60.04	72.38	82.95

Recovery test

Samples were spiked with known quantities of inhibin B and assayed according to the assay procedure of the kit.

Serum samples	Endog. conc. (pg/mL)	Added conc. (pg/mL)	Expected conc. (pg/mL)	Measured conc. (pg/mL)	Ratio (%) Measured/Expected
S1	72.44	17.33	89.77	91.49	101.9
	73.68	53.19	126.9	129.8	102.3
	70.58	101.4	171.9	180.1	104.7
S2	45.82	12.32	58.13	59.43	102.2
	46.37	37.68	84.05	83.87	99.78
	44.96	73.06	118.0	123.9	105.0
S3	27.05	7.519	34.57	35.93	103.9
	25.69	21.55	47.24	46.31	98.03
	26.74	44.93	71.67	70.87	98.89
S4	63.97	21.31	85.28	86.27	101.2
	65.36	65.09	130.5	127.7	97.92
	62.84	108.8	171.7	166.9	97.24
S5	47.45	15.17	62.62	62.85	100.4
	48.18	46.04	94.22	88.99	94.45
	46.40	88.67	135.1	129.6	95.94

Li-Hep plasma sample	Endog. conc. (pg/mL)	Added conc. (pg/mL)	Expected conc. (pg/mL)	Measured conc. (pg/mL)	Ratio (%) Measured/Expected
P1	19.63	6.87	26.50	28.61	108.0
	18.54	19.36	37.91	40.19	106.0
	19.45	41.23	60.68	55.98	92.26
P2	25.50	7.52	33.02	33.43	101.2
	23.95	21.10	45.06	46.78	103.8
	25.23	45.67	70.89	66.64	94.00
P3	48.28	14.07	62.34	63.78	102.3
	49.29	43.70	92.99	84.85	91.24
	47.36	83.97	131.3	114.5	87.18
P4	60.11	17.59	77.70	79.46	102.3
	61.71	54.92	116.6	117.8	101.0
	59.13	97.44	156.6	141.3	90.25
P5	51.62	15.39	67.01	66.41	99.10
	52.83	47.63	100.5	93.24	92.81
	50.56	91.65	142.2	132.9	93.48

Method Comparison

The Inhibin B Gen II ELISA (A81303) has been compared to two commercially available assays (Oxford Bio-Innovation (OBI) and Diagnostics Systems Laboratories (DSL)) using 60 serum male and 60 serum female samples, ranging in age from 20–50 years. Linear regression analysis of the results yielded the following:



Regression using n = 120 serum samples:

Inhibin B Gen II ELISA = 1.03 (OBI) - 6.77 pg/mL

(r = 0.99; P < 0.0001)

Inhibin B Gen II ELISA = 1.57 (DSL-10-84100) + 11.29 pg/mL

(r = 0.97; P < 0.0001)



Symbols Key

- REF** Product Reference / Référence du produit / Produktreferenz / Riferimento prodotto / Número de referencia del producto / Referência do produto / Produktreferens / Кодικός αναφοράς προϊόντος / 产品参考 / Gaminio nuoroda / Termékszám / Dane referencyjne produktu / Reference k produktu / Referenčné označenie výrobku / 제품 참조 자료 / Úrün Referansı / Ссылка на продукт / Референца за производ / 產品參考
- IVD** In Vitro Diagnostic / Diagnostic in vitro / In-vitro-Diagnostikum / Diagnostica in vitro / Para diagnóstico in vitro / Diagnóstico in vitro / InVitro-diagnostik / Για διάγνωση in vitro / 体外诊断 / In vitro diagnostika / In vitro diagnosztikai felhasználásra / Diagnostyka in vitro / Diagnostika in vitro / 체외 진단 / In Vitro Diagnostik / Диагностика in vitro / За ин витро диагностика / 體外診斷
- CONTENTS** Contents / Contenu / Inhalt / Contenuto / Contenido / Conteúdo / Περιεχόμενο / 组成 / Rinkinio sudėtis / Tartalom / Zawartość / Obsah / Obsah / 내용물 / İçindekiler / Содержание / Съдържание / 目錄
-  Manufactured by / Fabriqué par / Hergestellt von / Prodotto da / Fabricado por / Tillverkas av / Κατασκευαστής / 制造商 / Gamintojas / Gyártó: / Producent / Výrobce / Výrobca / 제조 / Üretici / Изготовлено / Произведено от / 製造商
-  Contains sufficient for <n> tests / Contenu suffisant pour "n" tests / Inhalt ausreichend für <n> Prüfungen / Contenuto sufficiente per "n" saggi / Contenido suficiente para <n> ensayos / Conteúdo suficiente para "n" ensaios / Råcker till "n" antal tester / Περιεχόμενο επαρκές για "n" εξετάσεις / 含量足够 <n> 次测试 / Turinio pakanka <n > tyrim / <n> teszthez elegendő mennyiséget tartalmaz / Zawartość wystarcza na <n> testów / Lze použít pro <n> testů / Obsah vystačí na <n > testov / <n> 테스트에 대해 충분한 양 포함 / <n> sayida test için yeterlidir / Содержит достаточно для количества тестов: <n> / Съдържа достатъчно за <n> теста / 內容物足夠執行 <n> 次測試
- CE** CE Mark / Marquage CE / CE-Kennzeichnung / Marchio CE / Marcado CE / Marcação CE / CE-märkning / Σήμανση CE / 标志 CE / ženklas / CE jelzés / Znak CE / Značka CE / Označenie CE / CE 표시 / CE İşareti / Маркировка CE / CE маркировка / CE 標識
- SDS** Safety Data Sheet / Fiche technique santé-sécurité / Sicherheitsdatenblatt / Scheda dati di sicurezza / Hoja de datos de seguridad / Ficha de Dados de Segurança / Säkerhetsdatablad / Φύλλο Δεδομένων Ασφάλειας / 安全数据单 / Saugos duomenų lapas / Biztonsági adatlap / Karta Charakterystyki Bezpieczeństwa / Bezpečnostní list / Bezpečnostný list / 안전보건자료 / Güvenlik Bilgi Formu / Паспорт безопасности / Информационен Лист За Безопасност / 安全性資料表
-  Consult Instructions for Use / Consultez le mode d'emploi / Siehe Gebrauchsanweisung / Consultare le istruzioni per l'uso / Consulte las Instrucciones de uso / Instruções de utilização / Konsultera bruksanvisning / Συμβουλευτείτε τις οδηγίες χρήσης / 请参阅使用说明 / Skaitykite naudojimo instrukciją / Olvassa el a használati utasítást / Zapoznać się z instrukcją użycia / Postępujcie podle návodu k použití / Prečítajte si návod na použitie / 사용 안내 문의 / Kullanma Talimatına Başvurun / Обратитесь к инструкциям / Вижте Инструкциите за употреба / 請參閱使用說明
-  Temperature range(s) / Plage(s) de température / Temperaturbereich(e) / Intervallo(i) di temperatura / Intervalo(s) de temperatura / Intervalo(s) de temperatura / Temperaturintervall / Εύρος(-η) θερμοκρασίας / 温度范围 / Temperatūros diapazonas (-ai) / Hőmérséklet-tartomány(ok) / Zakres(y) temperatury / Rozsahy teplot / Rozsah(y) teploty / 온도 범위 / Szaklık aralıkları / Диапазон(-ы) температуры / Температурен(ни) диапазон(и) / 溫度範圍 請參閱使用說明
-  Caution / Précaution / Achtung / Attenzione / Precaución / Atenção / Försiktighet / Προσοχή / 注意事项 / Įspėjimas / Figelem / Uwaga / Upozornění / Upozornenie / 주의 / Dikkat / Внимание / 注意
-  Expiration Date / Date D'expiration / Verfallsdatum, Verw. bis: / Data Di Scadenza / Fecha De Caducidad / Data de validade / Utgångsdatum / Ημερομηνία λήξης / 失效日期 / Galiojimo data / Lejárati idő / Data ważności / Datum expirace / Datum expirácie / 만료 날짜 / Son Kullanma Tarihi / Срок годности / Срок на годност / 到期日
- LOT** Lot Number / Numéro de lot / Chargennummer / Numero di lotto / Lote número / Número de lote / Satsnummer / Αριθ. παρτίδας / 批次号 / partijos numeris / Tételszám / Numer serii / Číslo šarže / 로트 번호 / Lot Numarası / Номер партии / Номер на партида / 批號
-  Date of Manufacture / Date de Fabrication / Herstellungsdatum / Data di Fabricazione / Fecha de Fabricación / Data de Fabrico / Produktionsdatum / Ημερομηνία Παραγωγής / 生产日期 / Pagaminimo Data / Gyártás Dátuma / Data Produkcji / Datum Výroby / Datum Výroby / 제조 일자 / Üretim Tarihi / Дата Производства / Дата на Производство / 製造日期

SOLN STOP	Stopping Solution / Solution d'arrêt / Stopperlösung / Soluzione di arresto / Solución de Detención / Solução de paragem / Διάλυμα αναστολής / 终止液 / Stabdymo tirpalas / Leállító oldat / Roztwór zatrzymujący / Roztok pro zastavení / Zastavovací roztok / 정지 용액 / Durdurma Çözeltisi / Завершающий раствор / Разтвор за спиране / 终止溶液
BUF ASSAY	Assay Buffer / Tampon pour le dosage / Assay-Puffer / Tampone per le analisi / Tampón de análisis / Tampão de ensaio / Assay Buffer / Analysebuffer / Määrittyspuskuri / Ρυθμιστικό διάλυμα ανάλυσης / Analizés buferinis tirpalas / Assay puffer / Bufor do testu / Tlmiivý roztok / Tlumivý roztok / 분석 완충액 / Test Tamponu / Буфер для анализа / Буфер за анализи / 分析緩衝劑 / Soluție tampon analiză / Pufer za test / Test pufer
BIO CONJ CONC	Biotin Conjugate Concentrate / Concentré de conjugué biotine / Biotinkonjugat-Konzentrat / Concentrato del coniugato biotina / Concentrado de conjugado de biotina / Concentrado Conjugado de Biotina / Biotinkonjugat, koncentrat / biotinkonjugatkonzentrat / Biotiniinikonjugaatti, konsentraatti / Συμπύκνωμα συζεύγματος β-ιορίνης / Biotino konjugato koncentratas / Biotin konjugátum koncentrátum / Koncentrat konjugatu biotyiny / Koncentrát konjugátu biotinu / Koncentrát konjugátu biotinu / 비오틴 복합체 농축액 / Biotin Konjugat Konsantresi / Конъюгат биотина, концентрат / Концентрат на конюгат биотин / 濃縮生物素結合物 / Concentrat conjugat biotină / Koncentrat konjugata biotina / Koncentrat biotin konjugata / Biotine conjugaatconcentraat
STREP CONJ	Streptavidin Conjugate / Conjugué de streptavidine / Streptavidinkonjugat/ Coniugato streptavidina / Conjugado de estreptavidina / Streptavidinkonjugat / Συζευγμα στρεπταβιδίνης / 链霉亲和素酶联物 / Streptavidino konjugatas / Sztreptavidin konjugátum / Koniugat streptavidiny / Konjugat streptavidin / 스트렙타비딘 복합체 / Streptavidin Konjugat / Конъюгат стрептавидина / Стрептавидин конюгат / 鏈霉親和素結合
SOLN TMB	TMB Solution / Solution TMB / TMB-Lösung / Soluzione TMB / Solución de TMB / Solução TMB / TMB-lösning / Διάλυμα TMB / TMB 溶液 / TMB tirpalas / TMB oldat / Roztwór TMB / Roztok TMB / Rastopina TMB / TMB 용액 / TMB Çözeltisi / TMB, раствор / TMB Разтвор / TMB 溶液
CONJ DIL	Conjugate Diluent / Diluant pour le conjugué / Konjugat-Verdünnungsmittel / Diluente del coniugato / Diluyente de conjugado / Diluente de conjugado / Konjugatfortynder / Konjugatutspädningsmedel / Αρχαιτικό συζεύγματος / Rozcieńczalnik koniugatu / Diluent pro konjugát / Redőítő za konjugat / Konjugat Dilüent / Разбавитель для конъюгата / Разредитель на конюгат / Conjugaatverduuner
SOLN WASH 20X	Wash Solution Concentrate 20X / Solution de lavage concentrée 20X / Waschlösungskonzentrat 20X / Concentrato di soluzione di lavaggio 20X / Solución de lavado concentrada 20X / Concentrado de solução de lavagem 20X / Tvättlösningskoncentrat 20X / Συμπυκνωμένο διάλυμα πλύσης 20X / 浓缩清洗液 20X / Plovimo tirpalo koncentratas 20X / 20X mosóoldat koncentrátum / Koncentrat 20X roztworu płuczącego / Koncentrát mycího roztoku 20X / Koncentrát premyvacieho roztoku 20X / 농축 세척액(20배) / Yıkama Çözeltisi Konsantresi 20X / Концентрат промывочного раствора 20X / Концентрат на разтвор за промиване 20X / 清洗溶液濃縮 20X
PLATE	Plate / Plaque / Platte / Piastra / Placa / Platta / Πλάκα / 板 / Pločké / Lemez / Plytka / Deska / Doštička / 판 / Plaka / Планшет / Чашка / 滴盤
IFU	Instruction for Use / Mode d'emploi / Gebrauchsanweisung / Istruzioni per l'uso / Instrucciones de uso / Instruções de utilização / Bruksanvisning / Οδηγίες χρήσης / 使用说明 / Naudojimo instrukcija / Használati utasítás / Instrukcja użycia / Návod k použití / Návod na použitie / 사용 안내 / Kullanna Talimati / Инструкции / Инструкции за употреба / 使用说明
	Biohazard / Risque biologique / Biogefährdung / Rischio biologico / Riesgo biológico / Risco biológico / Biologisk fara / Βιολογικός κίνδυνος / 生物危害 / Biologisk fara / Veszélyes biológiai anyag / Zagrożenie biologiczne / Biologické riziko / Biologické riziko / 생물학적 위험 / Biyolojik tehlike / Биологическая опасность / Биологична опасност / 生物危害

TRADEMARKS

‡ProClin is a trademark of LANXESS Corp.

‡‡Analyse-it is a trademark of Analyse-it Software, Ltd.

‡‡‡Microsoft and Microsoft Excel are trademarks of Microsoft Corporation.

REFERENCES

1. Kolon TF, Herndon CD, Baker LA, Baskin LS, Baxter CG, Cheng EY, Diaz M, Lee PA, Seashore CJ, Tasian GE, Barthold JS; American Urological Association. Evaluation and treatment of cryptorchidism: AUA guideline. J Urol. 2014 Aug;192(2):337-45. doi: 10.1016/j.juro.2014.05.005. Epub 2014 May 20. PMID: 24857650.
2. Salonia A, et al. European Association of Urology Guidelines on Sexual and Reproductive Health. 2021 March. Sexual and Reproductive Health | Uroweb
3. Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, Colombo N; ESMO Guidelines Committee. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv1-iv18. doi: 10.1093/annonc/mdy001. PMID: 29697741.
4. Johannsen T H, et al. Peptide hormone analysis in diagnosis and treatment of Differences of Sex Development: joint position paper of EU COST Action 'DSDnet' and European Reference Network on Rare Endocrine Conditions. European Journal of Endocrinology. 2020 Jun; 182(6):1-15. https://doi.org/10.1530/EJE-19-0831
5. Rifai N., Horvath A.R., Wittwer C.T.: Tietz textbook of clinical chemistry and molecular diagnostics and molecular diagnostics. 6th edition. Elsevier, St. Louis, Missouri, 2018, p 442, 629, 1622
6. Approved Guideline - Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, EP17-A2. June 2012. Clinical and Laboratory Standards Institute.
7. Approved Guideline – Evaluation of Precision of Quantitative Measurement Procedures, EP05-A3. October 2014. Clinical and Laboratory Standards Institute.
8. Approved Guideline - Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach, EP06-A. April 2003. Clinical and Laboratory Standards Institute.
9. J Bjerner et al. - Immunometric Assay Interference - Incidence and Prevention; Clin Chem 48;4; 613-621, 2002
10. L J Kricka - Interferences in Immunoassay - Still a Threat; Clin Chem 46, No. 8, 2000
11. A. Dasgupta: Biotin and Other Interferences in Immunoassays – A Concise Guide. Elsevier, St. Louis, 2019
12. Alan H.B. WU, PhD, DABCC, FACB: Tietz Clinical Guide To Laboratory Tests, 4th edition. W.B. Saunders Company, Philadelphia, 2006

13. Muttukrishna S, Ledger W, eds. 2001. Inhibin, activin and follistatin in human reproductive physiology. Imperial College Press, London, UK.
14. Welt C, Sidis Y, Keutmann, H, Schneyer A. 2002. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. *Exp Biol Med* 227:724-752.
15. Knight PG, Beard AJ, Wrathall HM, Castillo RJ. 1989. Evidence that the bovine ovary secretes large amounts of monomeric inhibin alpha subunit and its isolation from bovine follicular fluid. *J Mol Endocrinol* 2:189-200.
16. Schneyer AL, Sluss PM, Whitcomb RW, Martin KA, Sprengel R, Crowley WF Jr. 1991. Precursors of alpha-inhibin modulate FSH receptor binding and biological activity. *Endocrinology* 129:1987-1999.
17. Robertson DM, Sullivan J, Watson M, Cahir N. 1995. Inhibin forms in human plasma. *J Endocrinol* 144:261-269.
18. Robertson D, Burger HG, Sullivan J, Cahir N, Groome N, Poncelet E, Franchimont P, Woodruff T, Mather JP. 1996. Biological and immunological characterization of inhibin forms in human plasma. *J Clin Endocrinol Metab* 81:669-676.
19. Groome NP, Evans LW. 2000. Does measurement of inhibin have a clinical role? *Ann Clin Biochem.* 37:419-431.
20. Burger HG, Robertson DM. 1997. Editorial: inhibin in the male - progress at last. *Endocrinology* 138:1361-1362.
21. Klingmuller D, Haidl G. 1997. Inhibin B in men with normal and disturbed spermatogenesis. *Hum Reprod* 12:2376-2378.
22. Pierik FH, Vreeburg JT, Stijnen T, De Jong FH, Weber RF. 1998. Serum inhibin B as a marker of spermatogenesis. *J Clin Endocrinol Metab* 83:3110-3114.
23. Anawalt BD, Bebb RA, Matsumoto AM, Groome NP, Illingworth PJ, McNeilly AS, Bremner WJ. 1996. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. *J Clin Endocrinol Metab* 81:3341-3345.
24. Hayes FJ, Pitteloud N, DeCruz S, Crowley WF Jr, Boepple PA. 2001. Importance of inhibin B in the regulation of FSH secretion in the human male. *J Clin Endocrinol Metab* 86:5541-5546.
25. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. 1996. Measurement of dimeric inhibin B throughout the human menstrual cycle. *J Clin Endocrinol Metab* 81:1401-1405.
26. Lockwood GM, Muttukrishna S, Ledger WL. 1998. Inhibins and activins in human ovulation, conception and pregnancy. *Hum Reprod Update* 4:284- 295.
27. Welt CK, McNicholl DJ, Taylor AE, Hall JE. 1999. Female reproductive aging is marked by decreased secretion of dimeric inhibin. *J Clin Endocrinol Metab* 84:105-111.
28. Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Bert CA. 1997. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. *Fertil Steril* 67:110-114.
29. Seifer DB, Scott RT Jr, Bergh PA, Abrogast LK, Friedman CI, Mack CK, Danforth DR. 1999. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. *Fertil Steril* 72:63-65.
30. Dzik A, Lambert-Messerlian G, Izzo VM, Soares JB, Pinotti JA, Seifer DB. 2000. Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. *Fertil Steril* 74:1114-1117.
31. Danforth DR, Arbogast LK, Mroueh J, Kim MH, Kennard EA, Seifer DB, Friedman CI. 1998. Dimeric inhibin: a direct marker of ovarian aging. *Fertil Steril* 70:119-123.
32. Santoro N, Adel T, Skumick JH. 1999. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. *Fertil Steril* 71:658-662.
33. Tinkanen H, Bläuer M, Laippala P, Tuohimaa P, Kujansuu E. 2001. Correlation between serum inhibin B and other indicators of the ovarian function. *Eur J Obstet Gynecol Reprod Biol* 94:109-113.
34. Ludlow H, Muttukrishna S, Hyvönen M, Groome, NP. 2008. Development of a new antibody to the human inhibin/activin betaB subunit and its application to improved inhibin B ELISAs. *J Immunol Methods* 329:102-111.
35. Approved Guideline - Interference Testing in Clinical Chemistry, EP07 3rd Edition. April 2018. Clinical and Laboratory Standards Institute.



IMMUNOTECH s.r.o., Radiova 1122/1, 102 00 Prague 10, Czech Republic
www.beckmancoulter.com